Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Promising news for older AML patients

    ... of venetoclax with either decitabine or azacitidine was associated with a 69% overall responses rate, reported ... “Venetoclax, when combined with decitabine or azacitidine, has a tolerable safety profile in treatment-naive elderly patients ...

    Article last updated 07/19/2017 - 11:19am.

  2. Making Progress for Myelodysplastic Syndromes

    ... made some progress with current medications like Vidaza ( azacitidine ), Dacogen ( decitabine ), Revlimid ( lenalidomide ...

    Article last updated 07/26/2017 - 10:25am.

  3. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

    ... AIM: Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were ... of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS: In this ...

    Research Article last updated 02/03/2017 - 10:05am.

  4. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

    ... activity in patients with MDS and in vitro synergy with azacitidine . METHODS: A phase 2 randomized, placebo -controlled clinical trial of azacitidine and pracinostat was conducted in patients who had International ...

    Research Article last updated 02/03/2017 - 11:12am.

  5. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

    ... or transformation to acute myeloid leukemia (AML). Azacitidine was the first DNA hypomethylating agent approved by the United ... survival is independent of achieving a complete remission. Azacitidine has been used in older patients with both clinical and ...

    Research Article last updated 02/01/2017 - 8:17am.

  6. I Was Alone With MDS Until I Connected With Others on Social Media

    ... the exposure to infection.   This adjustment to azacitidine was a nightmare as I experienced more diarrhea, fever, pain and ...

    Patient Chronicle last updated 12/12/2017 - 12:06pm.

  7. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.

    ...

    Research Article last updated 03/09/2017 - 1:43pm.

  8. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

    ... The hypomethylating agents (HMAs) azacitidine and decitabine are both approved for treatment of ... on the HMA received in adjusted analysis (decitabine versus azacitidine, hazard ratio = 1·06, 95% confidence interval: 0·94-1·19, ...

    Research Article last updated 10/06/2016 - 11:34am.

  9. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase ...

    Research Article last updated 12/09/2015 - 8:56am.

  10. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

    ... The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular ... the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of ...

    Research Article last updated 02/04/2014 - 1:32pm.